Investigational product portfolio

BGB-43395 CDK4 inhibitor

• Phase 1: Breast cancer

BG-68501* CDK2 inhibitor

• Phase 1: Breast cancer

BGB-21447 next-gen BCL-2 inhibitor

• Phase 1: Metastatic breast
  cancer^†

Zanidatamab^‡ HER2 BsAb

• Phase 3: 1L HER2+ GEA

Tislelizumab-jsgr PD-1 mAb

• Phase 3: Locally advanced ESCC

Xaluritamig^§ STEAP1 x CD3 BsAb

• Phase 1: mCRPC

Tislelizumab PD-1 mAb

• Phase 1: Pan-tumor (subcutaneous formulation)

Tarlatamab^§ DLL3 x CD3 BsAb

• Phase 3: 2L SCLC, 1L ES-SCLC, LS-SCLC
• Phase 2: 3L SCLC

Tislelizumab PD-1

• Phase 3: 1L UBC

Pamiparib PARP inhibitor

• Phase 3: 2L methotrexate gBRCAm PSOC

BGB-30813 DGKζ inhibitor

• Phase 1: Solid tumors

BGB-A3055 CCR8 mAb

• Phase 1: Solid tumors

BGB-43395 CDK4 inhibitor

• Phase 1: Solid tumors

BG-68501^* CDK2 inhibitor

• Phase 1: Solid tumors

BG-C9074^|| B7H4-ADC

• Phase 1: Solid tumors

BGB-53038 pan-KRAS inhibitor

• Phase 1: Solid tumors

BG-60366 EGFR CDAC

• Phase 1: Solid tumors

BG-58067 MTA-cooperative PRMT5 inhibitor

• Phase 1: Solid tumors

SHY-2039 MAT2A inhibitor^¶

• Phase 1: Solid tumors

BG-C354 B7-H3 ADC

• Phase 1: Solid tumors

BG-C477 CEA ADC

• Phase 1: Solid tumors

BG-C137 FGFR2b ADC

• Phase 1: Solid tumors

BG-T187 EGFR x MET TsAb

• Phase 1: Solid tumors

BGB-R046 IL-15 prodrug

• Phase 1: Solid tumors

BGB-B2033 GPC3 x 4-1BB BsAb

• Phase 1: Solid tumors

BGB-B3227 MUC1 x CD16A BsAb

• Phase 1: Solid tumors